RR MedSciences is dedicated to driving change and transforming lives by forging a new path in the treatment of pain and inflammatory conditions
Founded in 2014, RR MedSciences is a clinical-stage biopharmaceutical company responsible for the patented small-molecule complex RM191A.
This novel complex is the foundation for RR MedSciences platform technology and product pipeline.
We are focused on the development of novel analgesics for the treatment of neuropathic, inflammatory and skeletal pain, and the development of therapeutics for the treatment of inflammatory driven conditions.
RR MedSciences directs extensive pre-clinical research and clinical trials in collaboration with research teams at the Australian Centre for Nanomedicine, the ARC Centre of Excellence in Convergent Bio-Nano Science, Sydney University, University of NSW, and Macquarie University.
Our team is highly accomplished with decades of clinical, medical and entrepreneurial business and product development expertise. We are specialists in formulation chemistry and bio-med product development with a particular focus on pain and inflammatory-related diseases.
Our collaborators are specialist researchers and clinicians in the fields of chemistry and physiology, bio-molecular science, biology, neurology, neuroscience, pain, cardiology, clinical oncology and ophthalmology.
Llewellyn has an extensive career in corporate management and in bio-chem medical research and product development. With MD or CEO roles, Llewellyn has led drug and product development at multiple Australian bio-med companies, including an ASX listed biotech, a biotech incubator, an international veterinary pharmaceutical, and an Australian medical device company prior to RR MedSciences.
Llewellyn’s research career spans more than thirty years. After a BAppSc Chemistry at Monash University he was recruited to an elite global development team at Nicholas (Kiwi) International, with positions in Australia, the UK and USA. After a time in corporate management in the financial sector, he returned to his love of med-tech.
Llewellyn has a specialty in the development of metallo-complexes, anti-inflammatory drugs and novel formulation expertise. He is responsible for RR MedSciences' core drug discovery and its research collaborations. Llewellyn is cited on the Redox Biology Jan 2021 Journal overview of the multiple studies of the RM191A compound on the skin.
Helena Libershal Casbolt
Helena is a new technology development specialist with MD, CEO and founder roles in technology commercialisation or bio-med start-ups and media / communication companies in both the USA and Australia. She has extensive entrepreneurial expertise and successful fundraising experience in the United States and Australia.
Helena's experience in business spans various sectors including bio-med product and business development, public / private health partnerships, consumer health products, e-commerce, online financial services, satellite and media technology, marketing, and corporate communications.
At RR MedSciences, Helena leads corporate communications and med-tech relations, co-manages strategy and commercial product development. She leads the commercial subsidiary of RR MedSciences, the Blue Healer brand and product development, DTC marketing, advertising and e-commerce.
Sofia Casbolt (BSc, BA)
Strategy and Operations
Over a decade’s experience as a program strategist and ops manager, Sofia is skilled in process improvement, project management and overarching strategy.
RR MedSciences' Scientific Advisors are leaders in their fields and bring independent views to our development based on their extensive careers in areas of medicine and research.
Professor Kerry-Anne Rye (BSc (hons), PhD, FAHA)
Head of lipid research group, Deputy head research, school of Medical Sciences, University of New South Wales, Sydney
Professor Kerry-Anne Rye (BSc (Hons), PhD, FAHA) is Head of the Lipid Research Group, Deputy Head (Research) School of Medical Sciences at UNSW Sydney. Fellow of the ASBMB in recognition of her research contributions to molecular life sciences. She co-editor Journal of Lipid Research. Past-Chair of the American Heart Association Scientific Sessions Program Committee (Arteriosclerosis, Thrombosis and Vascular Biology (ATVB) Council nominee) and Chair of the American Heart Association ATVB Council.
Prof Rye is recognised internationally for her work on high density lipoprotein (HDL) structure and function. She was the first to report that HDLs have anti-diabetic and anti-inflammatory properties. Her current research is focussed on understanding the roles of HDLs in the pathogenesis of cardiovascular disease and diabetes, and the development of new HDL-based therapies for these disorders.
Prof Rye has published over 270 papers in high impact peer reviewed journals that have attracted more than 20,000 citations. She is the Editor-in-Chief of the Journal of Lipid Research, serves as a regular Guest Editor for the Journal of the American Heart Association (JAHA) and is an Editorial Board Member of the ATVB journal.
Professor Pall Thordarson (BSc, PhD, CChem, FRACI, FRSC)
Director of the UNSW RNA Institute, Professor, School of Chemistry, University of New South Wales, Sydney
Professor Pall Thordarson (Palli) is the Director of the UNSW RNS Institute, a science, therapeutics and translational facility for driving approaches to global challenges in RNA chemistry, biology and medicine. He is a Professor at the School of Chemistry at the UNSW Sydney. Prof Thordarson is the President (elect) of the Royal Australian Chemical Institute (RACI) and he serves on the Scientific Advisory Board for Microscopy Australia and as a Management Committee Member for the ARC Training Centre for the Chemical Industries.
Prof Pall Thordarson obtained his BSc from the University of Iceland in 1996 and a PhD in Chemistry from The University of Sydney in 2001. Following a Marie Curie Fellowship in the Netherlands he returned to Australia in 2003 and was then appointed at UNSW Sydney in 2007 as a Senior Lecturer. He was awarded an ARC Future Fellowship in 2012 and promoted to full Professor in 2017. To date 19 PhD students and over 30 BSc Honours students have completed their research training under his guidance.
Prof Thordarson's research is in the area of bio-mimetic chemistry with a focus on nanomedicine, supramolecular and biophysical chemistry. With over 130 publications, including in prestigious journals such as Nature and Nature Nanotechnology, his research from Nanomedicine and Light-harvesting Materials to Supramolecular and Systems Chemistry, including Origin of Life. He is focused on advancing our understanding of how molecules interact with one another and ‘self-assemble’ and how we can then harness self-assembly to create novel functional materials and systems. He has received a number of awards including the 2012 Le Fèvre Memorial Prize from the Australian Academy of Science for outstanding basic research in Chemistry by a Scientist under the age of 40.
Professor Tony Sedgwick
Swansea University Medical School; Biosciences Advisor
Tony is an experienced entrepreneurial executive. He has held various senior leadership positions in R&D, becoming World-Wide Head of Clinical Operations for Roche. His product successes include Invirase and Tamiflu, which have had significant impact both medically and commercially.
Tony has been Chief Executive Officer of four biotechnology companies, with two of them successfully exited. He has also been chairman of a number of European and British Biotechnology companies.
Tony completed his PhD in Experimental Pathology at St Bartholemews Hospital Medical School in London. He is a Fellow of the Royal College of Pathologists and an honorary Professor at Swansea University Medical School.